Key Insights

Highlights

Success Rate

85% trial completion

Published Results

15 trials with published results (47%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

12.5%

4 terminated out of 32 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

31%

10 trials in Phase 3/4

Results Transparency

68%

15 of 22 completed with results

Key Signals

15 with results85% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (1)
P 1 (3)
P 2 (8)
P 3 (8)
P 4 (2)

Trial Status

Completed22
Terminated4
Unknown2
Recruiting2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT01273129Recruiting

Surgery as a Treatment for Medically Intractable Epilepsy

NCT03478852Recruiting

Investigating Epilepsy: Screening and Evaluation

NCT04903314Phase 1CompletedPrimary

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

NCT05067634Phase 3Active Not RecruitingPrimary

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT01866111Phase 2CompletedPrimary

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT00957047Phase 3CompletedPrimary

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

NCT02535091Phase 3CompletedPrimary

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT00465517Phase 2CompletedPrimary

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

NCT01397968Phase 2CompletedPrimary

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

NCT02076698Phase 3CompletedPrimary

Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy

NCT04513860UnknownPrimary

Cenobamate Expanded Access Program (EAP)

NCT01496612Phase 2Terminated

Buspirone Therapy for Localized Epilepsy

NCT00988429Phase 3CompletedPrimary

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00706160Completed

Language Mapping in Patients With Epilepsy

NCT00982787Phase 2WithdrawnPrimary

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT01281956Phase 2Terminated

PRX-00023 Therapy in Localization-Related Epilepsy

NCT00001932CompletedPrimary

Serotonin Receptors in Seizure Disorders

NCT00908349Phase 3CompletedPrimary

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT01190098Phase 4CompletedPrimary

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01090934Not ApplicableCompletedPrimary

Localizing the Epileptogenic Zone With High Resolution Electroencephalography

Scroll to load more

Research Network

Activity Timeline